Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38977 PHREESIA, INC. (Exact name of registrant as specified in its charter) Delaware 20-2275479 (State or othe ...

Financial Data and Key Metrics Changes - The average healthcare services clients increased by 33% year-over-year [10] - Revenue outlook for the year is maintained at $271 million to $275 million, implying a growth of 27% to 29% year-over-year [11] - Adjusted EBITDA outlook improved to a range of negative $126 million to negative $122 million, up from a prior outlook of negative $154 million to negative $149 million [13] Business Line Data and Key Metrics Changes - Life sciences growth was up 51% year-over-year, although revenue decreased slightly by $563,000 sequentially from Q4 [12] Market Data and Key Metrics Changes - Patient utilization trends were slightly below expectations, which may persist throughout the year [11] Company Strategy and Development Direction - The company focuses on building great products and expanding its client base, emphasizing a "land and expand" strategy [21][24] - Management is committed to addressing social determinants of health, aiming to empower providers rather than monetizing these services [33] Management's Comments on Operating Environment and Future Outlook - Management noted a mixture of COVID-related issues affecting both staff and patient attendance, impacting overall patient utilization trends [30] - The company is confident in its ability to achieve profitability by fiscal 2025, with expected revenue growth at a CAGR of 28% and expenses growing at 10% to 11% [77] Other Important Information - The company has maintained a consistent subscription revenue per provider client at $11,500 for several quarters [21] - The current cash balance and line of credit are deemed sufficient to finance the company's plans to achieve its 2025 targets [77] Q&A Session Summary Question: Dynamics around revenue per provider client and decline - Management explained that the decline is due to a "land and expand" strategy where new clients initially generate lower revenue [21] Question: Update on patient utilization trends - Management indicated that trends are influenced by a combination of COVID impacts and staffing issues [30] Question: Update on social determinants of health offering - Management emphasized the importance of addressing social determinants without monetizing them, focusing on empowering providers [33] Question: Insights on subscription revenue per client - Management noted low churn rates and success in upselling and cross-selling, indicating a strong customer retention strategy [64] Question: Pipeline for enterprise clients - Management stated that the go-to-market strategy remains consistent, focusing on delivering value and continuous engagement with clients [104] Question: Changes in marketing and campaign scrutiny - Management acknowledged increased scrutiny on marketing effectiveness and a shift away from traditional advertising methods [94]

Investor Presentation June 2022 DISCLAIMER This presentation includes express or implied statements that are not historical facts and are considered forward- looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events or our future financial or operating performance and may contain projections of our future results of operations or of our financial informa ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38977 PHREESIA, INC. (Exact name of registrant as specified in its charter) Delaware 20-2275479 (State or oth ...

Phreesia, Inc. (NYSE:PHR) Q4 2022 Earnings Conference Call March 30, 2022 5:00 PM ET Company Participants Balaji Gandhi - SVP, IR Chaim Indig - CEO and Co-Founder Randy Rasmussen - CFO Conference Call Participants Anne Samuel - JPMorgan Thomas Kelliher - RBC Capital Markets Jessica Tassan - Piper Sandler Richard Close - Canaccord Genuity Daniel Grosslight - Citigroup John Ransom - Raymond James Joy Zhang - SVB Leerink Glen Santangelo - Jefferies Ryan MacDonald - Needham & Company Joe Vruwink - Robert ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _ Commission File Number: 001-38977 PHREESIA, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-2275479 (State or Other J ...

Investor Presentation January 2022 DISCLAIMERS AND FORWARD-LOOKING STATEMENTS This presentation includes express or implied statements that are not historical facts and are considered forward- looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Forward-looking statements involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or our future financial or operating performance and may contain projectio ...

Phreesia, Inc. (NYSE:PHR) Q3 2022 Earnings Conference Call December 9, 2021 8:45 AM ET Company Participants Balaji Gandhi - SVP, IR Chaim Indig - CEO and Co-Founder Randy Rasmussen - CFO Conference Call Participants John Ransom - Raymond James Anne Samuel - JPMorgan Richard Close - Canaccord Genuity Glen Santangelo - Jefferies Ryan MacDonald - Needham Donald Hooker - KeyBanc Scott Schoenhaus - Stephens Daniel Grosslight - Citi Operator Good morning, ladies and gentlemen, and welcome to the Phreesia Fiscal T ...

Investor Presentation December 2021 DISCLAIMERS AND FORWARD-LOOKING STATEMENTS This presentation includes express or implied statements that are not historical facts and are considered forward- looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Forward-looking statements involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or our future financial or operating performance and may contain projecti ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38977 PHREESIA, INC. (Exact name of registrant as specified in its charter) Delaware 20-2275479 (State or o ...